Apratastat (10 mg/kg, i.p., administered twice at 4 and 16 hours post-induction) alleviats lung inflammation induced by Poly(I
) (HY-119307) and SARS-CoV-2 RBD-S protein in C57BL/6 mice[3].
Apratastat (10 mg/kg, p.o., once daily for 14 days) exhibits anti-tumor and anti-angiogenic activity in the MC38 xenograft C57BL/6 mouse model[4].
| Animal Model: | Poly(I
) (HY-107202) and SARS-CoV-2 RBD-S protein-induced lung inflammation model in C57BL/6 mice[3] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), administered twice at 4 and 16 hours post-surgery |
| Result: | Significantly reduced neutrophil and macrophage numbers in lung tissue, improved lung tissue morphology. |
| Animal Model: | MC38 colorectal cancer cell xenograft model in C57BL/6 mice[4] |
| Dosage: | 10 mg/kg |
| Administration: | Oral gavage (p.o.), once daily for 14 days |
| Result: | Significantly inhibited tumor growth, reduced tumor angiogenesis and lymphangiogenesis. |
